Navigation Links
Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million
Date:10/30/2008

program, a tender offer or any other means. In the event that demand for the repurchase of Class A shares amounts to less than $40 million, the Board of Directors may use the balance of the $40 million share authorization to repurchase Class B shares on the open market.

Revised 2008 Guidance

The Company's 2008 revised outlook is as follows:

* Total medical enrollment is expected to grow approximately 4-4.5

percent, with Medicare Advantage enrollment rising approximately

47-52 percent, up from our previous estimate of 45-48 percent.

* Consolidated operating revenues are now anticipated to be

$1.73-$1.76 billion, an increase from our prior estimate of

$1.70-$1.74 billion.

* Consolidated loss ratio is expected to be 84.5-85.0 percent, a 100

basis point increase from previous guidance, with the managed care

MLR now ranging between 88.5-89.0 percent, driven largely by the

Company's Medicare dual eligible product.

* Consolidated operating expense ratio is unchanged and anticipated to

be approximately 14.7 percent.

* The Company reduced its earnings per share expectation to

$1.72-$1.82 from $1.88-$1.98, based on 32.2 million weighted average

diluted shares outstanding, which excludes net realized and

unrealized gains (losses) on investments and derivatives.

Conference Call and Webcast

Management will host a conference call and webcast Thursday, October 30 at 10:00 a.m. Eastern Time to discuss its financial results for the third quarter and nine months ended September 30, 2008, as well as expectations for future earnings. To participate, callers within the U.S. and Canada should dial 1-800-257-3401, and international callers should dial 1-303-262-2141 about five minutes before the presentation.

To listen to the webcast, participants should visit the Investor Relat
'/>"/>

SOURCE Triple-S Management Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. Triple-S Management Corporation Schedules Second-Quarter Earnings Release and Webcast
2. Triple-S Management Corporation Reports First Quarter 2008 Results; Cites Growth Resulting From Strong Market Position
3. Triple-S Management Corporation Schedules First-Quarter Earnings Release and Webcast
4. Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007
5. Triple-S Management Corporation to Present at UBS Global Healthcare Conference
6. Triple-S Management Corporation Announces Full Exercise of Underwriters Over-Allotment Option
7. PharmaSmart International, Inc. Redefines Blood Pressure Management through Technology and Pharmacy Focused Patient Services
8. CareAnalyzer From DST Health Solutions Helps Health Plans Improve Care Management and Quality for Members
9. Wound Management Technologies, Inc. Announces Strategic Business Directions, Recent Conference Presentation, in Addition to Symposium Exhibit Plans for Las Vegas
10. Four Companies Are First to Achieve Accreditation Under Two New URAC Pharmacy Quality Management(SM) Programs
11. Alexion Pharmaceuticals Chooses Blue Mountain Regulatory Asset Manager(R) for Best-in-class Calibration Management Integrated with SAP(R)
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference 2ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference 3Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 3Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 3Drinking Your Way to Health 3F Perhaps Not 59700 1Drinking Your Way to Health 3F Perhaps Not 59700 2Drinking Your Way to Health 3F Perhaps Not 59700 3UCBs Cimzia 28R 29 28certolizumab pegol 29 Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid A 14516 1UCBs Cimzia 28R 29 28certolizumab pegol 29 Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid A 14516 2UCBs Cimzia 28R 29 28certolizumab pegol 29 Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid A 14516 3UCBs Cimzia 28R 29 28certolizumab pegol 29 Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid A 14516 4UCBs Cimzia 28R 29 28certolizumab pegol 29 Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid A 14516 5UCBs Cimzia 28R 29 28certolizumab pegol 29 Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid A 14516 6UCBs Cimzia 28R 29 28certolizumab pegol 29 Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid A 14516 7UCBs Cimzia 28R 29 28certolizumab pegol 29 Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid A 14516 8UCBs Cimzia 28R 29 28certolizumab pegol 29 Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid A 14516 9UCBs Cimzia 28R 29 28certolizumab pegol 29 Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid A 14516 10UCBs Cimzia 28R 29 28certolizumab pegol 29 Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid A 14516 11UCBs Cimzia 28R 29 28certolizumab pegol 29 Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid A 14516 12Video Games Can Play Havoc With Kids Joints 59696 1Video Games Can Play Havoc With Kids Joints 59696 2Video Games Can Play Havoc With Kids Joints 59696 3